Approximately $44 million and $125 million in preliminary (unaudited) Revuforj® (revumenib) 4Q25 and full year 2025 net revenue, respectively - ...
BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology ...
Ramp up of Phase 1 concentrator advancing to plan; first sale of concentrate completed Shaft #3 on track for April 2026; five ...
The community testing phase involves grassroots advisers and residents of Punggol Read more at The Business Times.
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales ...
As prominent artificial intelligence (AI) researchers eye limits to the current phase of the technology, a different approach ...
Voters across Myanmar went to the polls on Sunday for the second phase of the country's multiparty general election, with ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
Our deep pipeline and cash runway into 2030 enable IDEAYA to advance key combinations and to address multiple indications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback